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ABSTRACT
(57)
Disclosed are methods of using probiotic bacterial strains

Aneurinibacillus migulanus, Aneurinibacillus aneurinilyti
cus and / or extracts thereof for inhibiting the growth of
Streptococcus bovis, Fusobacterium necrophorum , and
Acranobacterium (Actinomyces) pyogenes. These bacterial
strains and /or their extracts can be used in cattle to treat
acidosis and/or liver abscesses , as well as inhibit foot rot ,
among other infections and conditions caused by Strepto

coccus bovis and /or Fusobacterium necrophorum and /or
Acranobacterium (Actinomyces ) pyogenes . Compositions
for use in these methods are also provided .
Specification includes a Sequence Listing .
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USE OF PROBIOTIC BACTERIAL STRAINS

AND CELL EXTRACTS TO INHIBIT
ACIDOSIS AND LIVER ABSCESSES IN
CATTLE

INCORPORATION OF SEQUENCE LISTING
[0001 ] A paper copy of the Sequence Listing and a com

bacteria , colonizes through the area of superficial necrosis
produced due to the acidity of the rumen contents. Leuko

toxin may facilitate resistance to phagocytosis . Bacterial

emboli from the lesions invade the hepatic portal venous

system and are transported to the liver, where they can
establish infectious foci of necrobacillosis that eventually
develop into abscesses .

puter readable form of the Sequence Listing containing the
file named “ 2016 - 079 ST25 . txt” , which is 2 , 582 bytes in size

10006 ] While there are current therapies available for
controlling liver abscesses , these therapies have met with

(asmeasured in MICROSOFT WINDOWS® EXPLORER ),

found to reduce the number of liver abscesses and increases
feed efficiency and weight gain , it has little , if any, effect on

are provided herein and are herein incorporated by refer
ence . This Sequence Listing consists of SEQ ID NOs: 1 - 2 .

BACKGROUND OF THE DISCLOSURE
[0002] The present disclosure relates generally to the use
of bacterial strains useful as probiotics . In some forms, these

little success. For example , while tylosin phosphate has been

prevalence of ruminal lesions . Further, with dairy cattle ,

percutaneous drainage and long -term therapy with procaine

penicillin G can be attempted , but the prognosis is poor.
Accordingly , the primary control is by managing ruminal

ticularly, the present disclosure is directed to the use of

acidosis through the method of feeding , adaptation using
diet composition , diligent feed bunk management, and use
of buffers in the diet.
[0007 ] Based on the foregoing, there is a need in the art for

Aneurinibacillus aneurinilyticus and their extracts for inhib
iting the growth of Streptococcus bovis , Fusobacterium

abscesses in livestocks, particularly , cattle . In some forms, it
would be beneficial if the therapy could be added directly to

bacterial strains synthesize and excrete antimicrobial com
pounds and extracts that have beneficial effects. More par

probiotic bacterial strains Aneurinibacillus migulanus and
necrophorum and Acranobacterium (Actinomyces ) pyo

genes. These bacterial strains and their extracts can be used
in cattle to treat acidosis and /or liver abscesses, as well as
inhibit foot rot, and other infections and conditions caused
by Streptococcus bovi and/ or Fusobacterium necrophorum

and /or Acranobacterium (Actinomyces ) pyogenes.
10003) Liver abscesses are seen in all ages and breeds of
cattle . They are most common in feedlot and dairy cattle fed
rations that are high in fermentable starches that predispose
the animal to acidosis and rumenitis . Cattle with acidosis

and liver abscesses have reduced production efficiency. The

affected livers are condemned at slaughter , and adhesions to

alternative therapies for reducing acidosis and /or liver

feed as a feed additive, or as a direct fed microbial (DFM )

product. In other forms, it would be beneficial if the therapy
could be formulated for topical application .

BRIEF DESCRIPTION OF THE DISCLOSURE
[0008 ] The present disclosure is generally related to the

use of probiotic bacterial strains Aneurinibacillus migulanus

and Aneurinibacillus aneurinilyticus and / or extracts thereof
for inhibiting the growth of Streptococcus bovis , Fusobac
terium necrophorum and Acranobacterium ( Actinomyces )
pyogenes. Growth of Streptococcus bovis, Fusobacterium

syndromes associated with posterior vena caval thrombosis .
[ 0004 ] Fusobacterium necrophorum , a gram -negative ,

necrophorum and Acranobacterium (Actinomyces ) pyo
genes has been linked to acidosis , which leads to liver
abscesses in livestock , as well as foot rot, particularly in
feedlot and dairy cattle . Accordingly, by inhibiting the
growth , the present disclosure can provide treatment for

rumen microflora , is the primary etiologic agent of liver

these conditions and ailments.
[0009 ] Accordingly, in one aspect, the present disclosure

surrounding organs or the diaphragm may necessitate car
cass trimming . Liver abscesses can also lead to disease

obligate anaerobic bacterium , and a component of normal
abscesses . Infection in the liver usually originates from a
necrobacillary rumenitis. Two biovars have been implicated .

is directed to a method of inhibiting Streptococcus bovis in

a subject in need thereof, the method comprising adminis

Biovar A ( F. necrophorum necrophorum ), the more virulent,

tering to the subject an effective amount of a bacterial strain

is the predominant biovar in the rumen microflora and is

selected from the group consisting of Aneurinibacillus migu

abscessation . Biovar B (F necrophorum funduliforme) is
commonly isolated from microabscesses in the rumen wall,
but is less commonly isolated from liver abscesses, in which

and combinations thereof. Preferably the inhibition is at
least 5 % ,more preferably at least 10 % , still more preferably

isolated , usually in pure culture , from most cases of liver

it is always found in mixed culture with biovar A or other
bacterial species . Acranobacterium (Actinomyces ) pyo

lanus , Aneurinibacillus aneurinilyticus or an extract thereof
at least 20 % , even more preferably at least 30 % , still more

preferably at least 40 % , even more preferably at least 50 % ,
still more preferably at least 60 % , even more preferably at

genes, Streptococci, Staphylococci, and Bacteroides spp are
most frequently recovered from mixed cultures .
[0005 ] Rumenitis is usually the result of rapid intra

least 70 % , still more preferably at least 80 % , even more
preferably at least 90 % , and most preferably between 95 %

quent production of lactic acid and increased acidity of the

to a method of inhibiting Fusobacterium necrophorum and

ruminal fermentation of dietary carbohydrate with subse

and 100 % .

[0010 ] In another aspect, the present disclosure is directed

ruminal fluid (“ grain overload " ) . Rations with high levels of

Acranobacterium (Actinomyces) pyogenes in a subject in

carbohydrate are the principal cause in both dairy and
feedlot cattle , but the texture of the feed and method of
feeding can be modifying factors . The incidence of rume
nitis in feedlot cattle is significantly higher when the cattle

need thereof, the method comprising administering to the
subject an effective amount of a bacterial strain selected

are transferred directly from a roughage ration to a high
starch (high energy ) finishing ration , and when there is poor
feed bunk management. F necrophorum , alone or with other

from the group consisting of Aneurinibacillus migulanus ,

Aneurinibacillus aneurinilyticus or an extract thereof and
combinations thereof. Preferably the inhibition is at least

5 % , more preferably at least 10 % , still more preferably at

least 20 % , even more preferably at least 30 % , still more
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preferably at least 40 % , even more preferably at least 50 % ,
still more preferably at least 60 % , even more preferably at
least 70 % , still more preferably at least 80 % , even more

preferably at least 90 % , and most preferably between 95 %
and 100 % .

[ 0011 ] In yet another aspect, the present disclosure is
directed to a method of reducing the incidence or severity of

acidosis in a subject in need thereof, the method comprising

administering to the subject an effective amount of a bac

terial strain selected from the group consisting of Aneurini
bacillus migulanus, Aneurinibacillus aneurinilyticus or an

extract thereof and combinations thereof. Preferably the

reduction is at least 5 % , more preferably at least 10 % , still

more preferably at least 20 % , even more preferably at least
30 % , still more preferably at least 40 % , even more prefer

ably at least 50 % , still more preferably at least 60 % , even

more preferably at least 70 % , still more preferably at least
80 % , even more preferably at least 90 % , and most prefer

ably between 95 % and 100 % .
[ 0012 ] In yet another aspect, the present disclosure is

directed to a method of reducing the incidence or severity of
liver abscesses or foot rot in a subject in need thereof, the

method comprising administering to the subject an effective
amount of a bacterial strain selected from the group con
sisting of Aneurinibacillus migulanus, Aneurinibacillus
aneurinilyticus or an extract thereof and combinations

thereof. In some forms, the reduction in the incidence of

liver abscesses is in comparison to a similar sized animal or
herd of animals and is based on the total number of liver
abscesses or foot rot lesions or the percentage of animals
with liver abscesses or foot rot. Preferably the reduction is
at least 5 % , more preferably at least 10 % , still more pref

erably at least 20 % , even more preferably at least 30 % , still
more preferably at least 40 % , even more preferably at least
50 % , still more preferably at least 60 % , even more prefer

ably at least 70 % , still more preferably at least 80 % , even

more preferably at least 90 % , and most preferably between
95 % and 100 % .

[ 0013] In another aspect, the present disclosure is directed

to a method of treating foot rot in a subject in need thereof,
the method comprising administering to the subject an

controlling is provided by having at least 5 % less progres
sion in severity or in the number of liver abscesses or areas
of foot rot or their severity , more preferably at least 10 % ,
still more preferably at least 20 % , even more preferably at
least 30 % , still more preferably at least 40 % , even more
preferably at least 50 % , still more preferably at least 60 % ,
even more preferably at least 70 % , still more preferably at
least 80 % , even more preferably at least 90 % , and most
preferably between 95 % and 100 % after receiving an admin
istration of a composition comprising the bacterial strains. In

some forms, this progression is measured by comparing the
number of liver abscesses or areas of foot rot from before the

administration of a composition comprising at least one of
the bacterial strains to the number of liver abscesses or areas

of foot rot after the administration of a composition com

prising at least one of the bacterial strains.
[0015 ] In another aspect, the present disclosure is directed
to a method of treating foot rot in a subject in need thereof,
the method comprising administering to the subject an
effective amount of a bacterial strain selected from the group
consisting of Aneurinibacillus migulanus, Aneurinibacillus
aneurinilyticus or extract thereof and any combination
thereof. In some forms, the administration comprises the

step of applying an amount of at least one of the bacterial
strains to the feet of a subject in need thereof. In some forms,
the bacterial strains will be incorporated into a gel, cream ,

spray , or lotion . In other forms, the bacterial strains will a

component in an aqueous medium that will be applied

topically to an area affected by foot rot. Preferred routes of
bath , and the like .
[0016 ] In yet another aspect, the present disclosure is
topical administration include spraying, submersion in a

directed to a composition comprising an amount of at least
one bacterial strain selected from the group consisting of

Aneurinibacillus migulanus, Aneurinibacillus aneurinilyti
cus or extract thereof and any combination thereof. In some

forms of the composition, both bacterial strains are present.
In some forms of the composition , the bacterial strains
include live cultures combined with feed . In some forms of

the composition , the bacterial strains are lyophilized . Such
their lyophilized form . Such lyophilized forms can also be

effective amount of a bacterial strain selected from the group

lyophilized forms can be reconstituted or administered in

aneurinilyticus or extract thereof and combinations thereof.

combined with feed . In some forms of the composition

consisting of Aneurinibacillus migulanus, Aneurinibacillus

[ 0014 ] In yet another aspect, the present disclosure is

including live cultures or lyophilized bacterial strains, the

bacterial strains are combined or mixed with a prebiotic .

directed to a method of controlling liver abscesses and /or
foot rot in an animal or herd of animals, the method

Such combinations can be added to feed . In some forms of

strain selected from the group consisting of Aneurinibacillus

administration . In some forms of the composition , the com
position is formulated for topical formulation .

abscesses and/or foot rot is in comparison to the animal or

directed to a kit comprising the composition as described
herein . In some forms, the kit includes a container for

abscesses or foot rot areas or the percentage of animals with
liver abscesses or foot rot before and after receiving a
composition comprising at least one of the bacterial strains .
A further comparison can be made to a similar sized animal

housing the components of the kit . In some forms, the kit

comprising administering an effective amount of a bacterial
migulanus, Aneurinibacillus aneurinilyticus or an extract
thereof and any combination thereof to an animal or to the
animals of the herd . In some forms, controlling liver

herd of animals and is based on the total number of liver

or herd of animals that has not received administration of a

composition comprising at least one of the bacterial strains.
In other forms, controlling is measured by comparing the

severity of the liver abscesses or foot rot before and after

receiving an administration of a composition comprising at
least one of the bacterial strains . Preferably evidence of

the composition , the composition is formulated for oral

[0017 ] In yet another aspect, the present disclosure is

includes instructions for use .
[0018 ] In still another aspect, the present disclosure is
directed to a foot bath comprising an amount of a bacterial
strain selected from the group consisting of Aneurinibacillus

migulanus, Aneurinibacillus aneurinilyticus or extract
thereof and any combination thereof in an aqueous environ
ment. Such a bath is configured for insertion of a foot or hoof
therein such that the aqueous portion of the bath contacts
portions of the hoof or foot susceptible to foot rot .
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BRIEF DESCRIPTION OF THE DRAWINGS
[0019 ] The patent or application file contains at least one

drawing executed in color. Copies of this patent or patent

application publication with color drawing ( s ) will be pro

vided by the Office upon request and payment of the

necessary fee .
[ 0020 ] The disclosure will be better understood , and fea
tures, aspects and advantages other than those set forth
above will become apparent when consideration is given to

the following detailed description thereof. Such detailed

description makes reference to the following drawings ,
wherein :
[0021] FIG . 1 depicts the results from initial screening
showing potential candidates that were used for further

screening as described in the Example . The antimicrobial
assay shown is against Streptococcus bovis ATCC 700410
( JB1). “ A ” denotes Aneurinibacillus migulanus and “ B ”
denotes Aneurinibacillus anerinilyticus UNL P2C12 show
ing inhibition of the growth of Streptococcus bovis . The
species identification was performed on the candidate iso
lates .

[0022 ] FIGS. 21 & 2B depict results of the antimicrobial
2A depicts 50 ul of cell extract from 24 -hour old culture of
Aneurinibacillus migulanus (“ A ” ) and Aneurinibacillus
anerinilyticus UNL P2C12 (“ B ” ) showing inhibition of the
growth of Streptococcus bovis. FIG . 2B depicts 50 ul of cell
free media from 72 -hour old culture of Aneurinibacillus
migulanus (“ A ” ) and Aneurinibacillus anerinilyticus UNL
P2C12 (“ B ” ) showing inhibition of the growth of Strepto
coccus bovis.
[0023] FIGS. 3A & 3B depict results of the antimicrobial
assay against Fusobacterium necrophorum ATCC 27852 .
assay against Streptococcus bovis ATCC 700410 ( JB1). FIG .

FIG . 3A depicts 50 ul of cell extract from 24 -hour old culture
of Aneurinibacillus migulanus (“ A ” ) and Aneurinibacillus
anerinilyticus UNL P2C12 (“ B ” ) showing inhibition of the

growth of Fusobacterium necrophorum . FIG . 3B depicts 50
ul of cell free media from 72 -hour old culture of Aneurini
bacillus migulanus (“ A ” ) and Aneurinibacillus anerinilyti

cus UNL P2C12 (“ B ” ) showing inhibition of the growth of
Fusobacterium necrophorum .

[ 0024 FIG . 4 depicts results of the antimicrobial assay
control showing that cell growth inhibition is not caused by

cell lysis buffer. “ A ” denotes Streptococcus bovis ATCC

700410 ( JB1) and “ B ” denotes Fusobacterium necrophorum
ATCC 27852 in the presence of 50 ul of lysis/ extraction
buffer. Little to no inhibition is seen compared to FIGS. 2 &

[ 0025 ] FIG . 5 depicts growth curves for Streptococcus
bovis ATCC 700410 ( JB1) in the presence of Aneuriniba

cillus anerinilyticus UNL P2C12 cell extract. The curves
demonstrate inhibition of growth of Streptococcus bovis
ATCC 700410 ( JB1) in the presence of cell extract. The
growth curves show that although there is a short lag , the
lysis /extraction buffer does not inhibit growth . The culture

growth was measured using optical density (OD ) at 595 nm .

Experiment was done in triplicate and mean values are

plotted .
10026 ] FIG . 6 depicts in vitro induction of acidosis using

glucose , showing protection of ruminal pH using the cell

extract and live cells . The cell extract shows a dose depen
dent response . Uninduced — No glucose induction , Induced

Uncontrolled - induced with glucose with no treatment, Cell

extract 1000 — induced with glucose in the presence of 1000

ul of crude cell extract, Cell extract 500 - induced with
glucose in the presence of 500 ul of crude cell extract, and
Live cells - induced with glucose in the presence of 10° live
Aneurinibacillus anerinilyticus UNL P2C12 cells. In the live
cells , a rapid initial pH drop is seen due to Aneurinibacillus
anerinilyticus UNL P2C12 cells utilizing the glucose added
to induce acidosis. However, protection is seen from the live
cells 5 hours after induction .

DETAILED DESCRIPTION

[0027 ] Unless defined otherwise, all technical and scien

tific termsused herein have the samemeaning as commonly

understood by one of ordinary skill in the art to which the

disclosure belongs . Although any methods and materials

similar to or equivalent to those described herein can be used
preferred methods and materials are described below .
[0028 ] In general, the present disclosure is related to the
use of probiotic bacterial strains Aneurinibacillus migulanus
and Aneurinibacillus aneurinilyticus, or extracts thereof, for
inhibiting the growth of Streptococcus bovis , Fusobacterium
in the practice or testing of the present disclosure , the

necrophorum and Acranobacterium (Actinomyces ) pyo

genes. Accordingly , the methods of the present disclosure

provide treatment for conditions and ailments resulting from
overgrowth of Streptococcus bovis, Fusobacterium necro
phorum and Acranobacterium (Actinomyces ) pyogenes, for
example , acidosis, liver abscesses, foot rot, and the like.
[0029 ] " Inhibit ” and/ or " reduce” or other forms of the
words and their synonyms, such as “ reducing ” or “ reduc

tion ,” refer to slowing the growth of the so - referenced
pathogen and/ or lowering its incidence . It is understood that
this is typically in relation to some standard or expected
value, in other words it is relative , but that it is not always

necessary for the standard or relative value to be referred to .
For example , " reduces the population of bacteria ” in certain

instances refer to lowering the amount of bacteria relative to
a standard or a control. One preferred control is a similar
animal or herd of animals that have not received an admin

istration of the compositions described herein . “ Inhibit” and
including pathogenic bacterial growth that would have oth

“ inhibition ” refer to slowing or deterring pathogen growth ,

erwise occurred except for the provision of the characterized
deterrent.
[0030 ] By “ treat ” or other forms of the word , such as

" treated ” or “ treatment,” means to administer a composition
or to perform a method in order to reduce , prevent, inhibit,

break - down, or eliminate a particular characteristic or event

or reducing , minimizing and/or eliminating diseases , con
ditions, ailments and / or symptoms thereof caused by bacte

rial growth , and in particular, growth of Streptococcus bovis,

Fusobacterium necrophorum and Acranobacterium (Actino
myces) pyogenes. In some embodiments , “ treatment” , “ treat

ing" , or " treat” refer to reversing the progression of condi
embodiments , " treatment”, “ treating ", or " treat” refer to
slowing or stopping the progression of conditions or ail
ments caused by growth of these bacteria. This would
include slowing or stopping the formation of new abscesses
or areas of foot rot or slowing or stopping the growth of
existing abscesses or areas of foot rot. In the context of a
herd , “ treatment” , “ treating " , or " treat" can also refer to
tions or ailments caused by growth of these bacteria . In other

reducing the number of animals that have liver abscesses or
areas of foot rot .
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[0031] Aneurinibacillus migulanus (formerly known as
Bacillus brevis ) is a producer of the bacteriocins Carnocy
clin A , Zoocin A , Enterolysin A , Linocin M18 , and uviB .

[0032] Similar properties are seen with Aneurinibacillus
aneurinilyticus ( formerly known as Bacillus aneurinolyti
cus ), which produces Zoocin A and uviB .

[ 0033] Both Aneurinibacillus migulanus and Aneuriniba

cillus aneurinilyticus are probiotic bacterial strains isolated

from rumen . It has been found that Aneurinibacillus migu

lanus and Aneurinibacillus aneurinilyticus synthesize and
excrete extracts that function as antimicrobial compounds ;
that is , that inhibit the growth of Streptococcus bovis,
Fusobacterium necrophorum and Acranobacterium (Actino

myces) pyogenes , bacterial strains typically linked to acido
sis , liver abscesses and foot rot in livestock .

[0034 ] It has been found that by inhibiting Streptococcus

bovis, Fusobacterium necrophorum and Acranobacterium
(Actinomyces ) pyogenes, the methods of the present disclo
sure can treat diseases , conditions and ailments associated
with infection by Streptococcus bovis , Fusobacterium

necrophorum and Acranobacterium (Actinomyces ) pyo
genes. Exemplary conditions include acidosis and / or its
direct conditions of liver abscesses and foot rot in livestock .
[0035 ] Other diseases, conditions and ailments can even
include sore throats such as observed in human subjects.
[0036 ] The methods of the present disclosure, therefore,
are directed to administering Aneurinibacillus migulanus
and Aneurinibacillus aneurinilyticus, or extracts thereof, to
a subject in need thereof. As used herein , “ subject in need

thereof” refers to a subset of subjects in need of reducing
and/ or inhibiting growth of Streptococcus bovis, Fusobac
terium necrophorum and Acranobacterium (Actinomyces )
pyogenes. In one embodiment, subjects that are in specific
need may include livestock , and in particular cattle, horses,

pigs, bison , and buffalo , who are susceptible to , or at

elevated risk of, infection by Streptococcus bovis, Fusobac

terium necrophorum and Acranobacterium ( Actinomyces )

pyogenes . Subjects may be susceptible to , or at elevated risk

of, infection due to environment, feed , and / or lifestyle .

While described herein in relation to cattle , it should be

understood that other livestock may be administered the
bacterial strains and/ or extracts thereof without departing

from the present disclosure. Further, the bacterial strains or
extracts thereof can be administered to subjects other than

herein may be administered in unit dosage forms and /or
formulations containing conventional nontoxic pharmaceu
tically -acceptable carriers , adjuvants , and vehicles .

[0038 ] Illustrative formats for oral administration include
tablets, capsules , elixirs, syrups, and the like . In some
embodiments , oral administration can be in the form of
toothpaste such as for the treatment of sore throats in
subjects.
[0039 ] In particularly suitable embodiments , the methods
of the present disclosure include incorporating Aneuriniba
cillus migulanus and /or Aneurinibacillus aneurinilyticus or
extracts thereof into the diet of the subject as a direct fed

microbial product. By way of example , the direct fed
microbial product can be used to supplement livestock feed

such as cattle feed , horse feed , pig feed , chicken feed , bison
feed , buffalo feed, duck feed , turkey feed and the like .

Suitable direct fed microbial products can include live
cultures or lyophilized preparations.
10040 ]. In another embodiment, the Aneurinibacillus migu

lanus and/or Aneurinibacillis aneurinilyticus or extracts
thereof are administered to the subject as a feed additive
such as an additive for use in any one or more of the above

livestock feeds. In one particular embodiment, the Aneurini

bacillus migulanus and /or Aneurinibacillis aneurinilyticus
or extracts thereof are administered in amounts ranging from

about 10 % to about 1011 colony forming units (CFU ). In some
preferred forms, the Aneurinibacillus migulanus and /or

Aneurinibacillis aneurinilyticus or extracts thereof are

administered in amounts ranging from about 10° to about

1010 CFU , with 10° CFU being particularly preferred .

[0041] Illustrative routes for parenteral administration
include intravenous, intraarterial, intraperitoneal, epidural,
intraurethral, intrasternal, intramuscular and subcutaneous,

as well as any other art recognized route of parenteral
administration .

[0042] Illustratively, administering includes local use ,
such as when administered locally to the site of inflamma
tion , infection , injury , or defect, or to a particular organ ( e. g .,

liver ) or tissue system . Illustrative local administration may

be performed during open surgery , or other procedures when
the site of inflammation , infection , injury , or defect is

accessible . Alternatively , local administration may be per
formed using parenteral delivery where the bacterial strains /

extracts described herein is deposited locally to the site

terium necrophorum and Acranobacterium (Actinomyces )

without general distribution to multiple other non - target
sites in the subject being treated . It is further appreciated that

thereof can be administered to companion animals ( e . g .,

locally in the surrounding tissue. Similar variations regard

livestock to inhibit growth of Streptococcus bovis, Fusobac

pyogenes. For example , the bacterial strains or extracts
dogs, cats ), humans , poultry (e.g ., chicken , duck , turkey ).

Based on the foregoing, because some of the method

embodiments of the present disclosure are directed to spe

cific subsets or subclasses of identified subjects ( that is, the
addressing one or more specific conditions noted herein ),

subset or subclass of subjects “ in need of assistance in

not all subjects will fall within the subset or subclass of

subjects as described herein for certain conditions and /or
ailments .

[ 0037] The term “ administering” as used herein includes

all means of introducing the bacterial strains and/ or their
extracts described herein to the subject, including, but not
limited to , including , but not limited to , oral ( po ) , intrave

nous ( iv ), intramuscular (im ), subcutaneous ( sc ), parenteral,
transdermal, inhalation , buccal, ocular, sublingual, vaginal,
rectal, and the like. The strains and /or extracts described

local administration may be directly in the injury site, or
ing local delivery to particular tissue types, such as organs,
and the like , are also described herein .
[0043] Suitable lubricants include, for example , water
based lubricants, oil-based lubricants, and silicone -based
lubricants . Particularly suitable lubricants include, for
example, glycerin , hydroxyethyl cellulose , xylitol, carra
geenan , and combinations thereof.

[0044] In yet other embodiments , administration includes
topical administration by use of a topical composition , such
as a spray composition, a lotion , an ointment, an aqueous
composition , or the like . When used as a topical composi
tion , the composition can include other components typi

cally included in topical sprays , lotions, and /or ointments in

combination with the Aneurinibacillus migulanus and /or

Aneurinibacillis aneurinilyticus or extracts thereof as known

in the topical arts without departing from the present dis

US 2019 /0269740 A1
closure. In one particularly suitable embodiment, the Aneu
rinibacillus migulanus and/ or Aneurinibacillis aneurinilyti-

cus or extracts thereof are incorporated into a composition in
the form of a foot bath such that a subject can contact the
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otics exert health benefits , which may include, but are not
limited to , selective stimulation of the growth and /or activity
of one or a limited number of beneficial gut bacteria ,

stimulation of the growth and /or activity of ingested probi

foot bath by walking through the bath to apply the compo

otic microorganisms, selective reduction in gut pathogens ,
and favorable influence on gut short chain fatty acid profile .

amount of Aneurinibacillus migulanus and / or Aneuriniba

[0045] In some embodiments, a therapeutically effective
cillis aneurinilyticus or extracts thereof in any of the various

Some combinations of Aneurinibacillus migulanus and/or
Aneurinibacillis aneurinilyticus or extracts thereof and / or at
least one prebiotic will act synergistically with one another.

forms described herein may be mixed with one or more
excipients, diluted by one or more excipients , or enclosed

developed through the genetic manipulation of organisms

sition .

within such a carrier which can be in the form of a capsule ,
sachet, paper, or other container. Excipients may serve as a
diluent, and can be solid , semi- solid , or liquid materials ,

Such prebiotics may be naturally -occurring, synthetic , or

and /or plants , whether such new source is now known or

developed later . Prebiotics useful in the present disclosure

may include soluble starch , yeast extract, oligosaccharides,

which act as a vehicle , carrier or medium for the active
ingredient. Thus, the Aneurinibacillus migulanus and /or
Aneurinibacillis aneurinilyticus or extracts thereof can be

polysaccharides, and other prebiotics that contain fructose ,
xylose , soya , galactose , glucose and mannose. Of these ,
soluble starch and yeast extract are particularly preferred for

syrups, aerosols (as a solid or in a liquid medium ), oint
injectable solutions , and sterile packaged powders.

fermentation has yeast and yeast extract as by products . Both

administered in the form of tablets, pills , powders , lozenges ,
sachets, cachets, elixirs, suspensions, emulsions , solutions,

ments, soft and hard gelatin capsules , suppositories , sterile

10046 ] The term “ therapeutically effective amount” as
used herein , refers to that amount of active compound or

agent that elicits the biological or medicinal response in a

tissue system , animal or human that is being sought by a
researcher, veterinarian , medical doctor or other clinician ,

which includes alleviation of the symptoms of the disease ,
condition or ailment being treated . In one aspect, the thera
peutically effective amount is that which may treat or

alleviate the condition , disease or symptoms of the disease
at a reasonable benefit/ risk ratio applicable to any medical

treatment. However, it is to be understood that the total
weekly usage of the Aneurinibacillus migulanus and/ or

Aneurinibacillis aneurinilyticus or extracts thereof

described herein may be decided by the attending physician

or veterinarian within the scope of sound medical judgment.
The specific therapeutically - effective dose level for any
particular patient will depend upon a variety of factors,
including the severity of the condition being treated ; the
specific composition employed ; the age, body weight, gen
eral health , gender and diet of the patient: the time of
administration, route of administration , and the duration of
the treatment; drugs used in combination or coincidentally

with the Aneurinibacillus migulanus and /or Aneurinibacillis

aneurinilyticus or extracts thereof; and like factors well

known to the researcher , veterinarian , medical doctor or

other clinician of ordinary skill .
[0047] It is also appreciated that the therapeutically effec
tive amount is advantageously selected with reference to any
toxicity , or other undesirable side effect, that might occur
during administration of the Aneurinibacillus migulanus
and/ or Aneurinibacillis aneurinilyticus or extracts thereof.

[ 0048 ] In particular embodiments, such as when the Aneu
rinibacillus migulanus and /or Aneurinibacillis aneurinilyti
cus or extracts thereof are administered as a feed additive ,
the Aneurinibacillus migulanus and /or Aneurinibacillis
aneurinilyticus or extracts thereof are administered in
amounts to provide from about 100 to about 1011 CFU ,more
preferably 108 to 1010 CFU , and most preferably about 109

CFU per head per day.

[0049 ] In some embodiments , the Aneurinibacillus migu

lanus and/or Aneurinibacillis aneurinilyticus or extracts
thereof are administered with at least one prebiotic . Prebi

some forms. Corn has a high amount of soluble starch and
distillers grains which comes as a by -product of ethanol

corn and distillers grains are widely used in cattle diets and

as such Aneurinibacillus migulanus and / or Aneurinibacillis

aneurinilyticus will grow well when mixed with corn or

distillers grains and fed .
[0050 ] More specifically, prebiotics useful in the present
disclosure may include soluble starch , yeast extract, poly
dextrose , polydextrose powder, lactulose, lactosucrose ,
raffinose , gluco -oligosaccharide , inulin , fructo -oligosaccha
ride, isomalto -oligosaccharide , soybean oligosaccharides,

lactosucrose , xylo - oligosaccharide , chito -oligosaccharide,
manno -oligosaccharide , aribino - oligosaccharide, siallyl-oli

gosaccharide , fuco -oligosaccharide, galacto -oligosaccha

ride, and gentio -oligosaccharides .
[0051 ] In an embodiment, the total amount of prebiotics
present in the composition may be from about 1.0 g/L to

about 10 .0 g /L of the composition .More preferably , the total

amount of prebiotics present in the nutritional composition
may be from about 2 .0 g/ L and about 8 .0 g /L of the

composition . In some embodiments , the total amount of

prebiotics present in the nutritional composition may be
from about 0 . 1 g / 100 kcal to about 1 g / 100 kcal. In certain

embodiments, the total amount of prebiotics present in the
about 0 .7 g/ 100 kcal.
[0052] The prebiotics of this disclosure can be in the same

nutritional composition may be from about 0 . 3 g / 100 kcal to
capsule or formulation as the probiotics , or in a separate

dosage form . The prebiotics of this disclosure may also be
taken with carbohydrate or fiber to increase their effective
ness .

[0053] The compositions of the present disclosure can also

include one or more additional active ingredients, excipi

ents, dissolution agents , surfactants , antioxidants, antisep

tics , preservatives, penetrants, and combinations thereof.
[0054 ] Various excipients can be mixed with the compo
sitions as would be known to those skilled in the art. Suitable
excipients include , for example , microcrystalline cellulose ,
colloidal silicon dioxide, lactose , starch , sorbitol, cyclodex
trin and combinations thereof.
[0055 ] Suitable dissolution agents include, for example ,
organic acids such as citric acid , fumaric acid , tartaric acid ,
succinic acid , ascorbic acid , acetic acid , malic acid , glutaric
acid and adipic acid , and can be used alone or in combina
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tion . These agents can also be combined with salts of the
acids, e .g . sodium citrate with citric acid , to produce a buffer

EXAMPLES

[ 0056 ] Suitable surfactants include, for example, sodium
lauryl sulphate , polyethylene separates , polyethylene sorbi
tan fatty acid esters, polyoxyethylene castor oil derivatives,
polyoxyethylene alkyl ethers, benzyl benzoate , cetrimide ,
cetyl alcohol, docusate sodium , glyceryl monooleate , glyc

[0064] In this Example , the inhibitory abilities of bacterial
strains against Streptococcus bovis and Fusobacterium
necrophorum were analyzed.
Methods
[0065 ] Isolation of the Bacterial Strains
[0066 ] Rumen samples were collected through a rumen
fistula from 4 animals . Each animal was on a different diet
( animal # 6396 — deoiled modified distillers plus solubles
with added corn oil; animal # 6393 — Full fat modified dis
tillers plus solubles ; animal #6398 _ dry rolled corn and high
moisture corn ; and animal # 6394 — deoiled modified distill
ers grains plus solubles). Equal amounts (~ 10 grams) of each

Example 1

system .

eryl monostearate , glyceryl palmitostearate, lecithin ,
medium chain triglycerides, monoethanolamine, oleic acid ,

poloxamers, polyvinyl alcohol and sorbitan fatty acid esters .
[0057 ] Suitable antioxidants include, for example, sodium
metabisulfite ; tocopherols such as a , ß , d -tocopherol esters
and a -tocopherol acetate ; ascorbic acid and pharmaceuti
cally acceptable salts thereof; ascorbyl palmitate; alkyl
gallates (e.g., propyl gallate, TENOX® PG , TENOX® S - 1);
sulfites and pharmaceutically acceptable salts thereof buty
lated hydroxyanisole; butylated hydroxytoluene; and mono
thioglycerol.
[0058 ) Suitable antiseptics include, for example, chlo
rhexidine gluconate , glucono delta -lactone , methylparaben ,
sodium hydroxide, and combinations thereof.
[0059 ] Suitable preservatives include parabens. Suitable

rumen sample were mixed together in a 50 ml conical tube
and sterile PBS was added to the top of the tube and shaken

vigorously for 5 minutes using a vortexer. Aliquotes of the
sample was incubated at 70° C . for 1 hour to reduce the

growth of vegetative cells. The sample was serially diluted
( 101 - 104) and plated on ISP 2 , ISP 4 and casein starch agar
(Himedia Laboratories , India ) with 50 ug/ml cycloheximide

include isobutylparaben , isopropylparaben , benzylparaben
and their sodium salts.
[0060] Suitable penetrants include , for example , sulphox
ides (e. g ., dimethyl sulphoxide, dimethylacetamide, dimeth
ylformamide ), azone (1 -dodecylazacycloheptan -2 -one or
laurocapran ), pyrrolidones (e. g., N -methyl -2 -pyrolidone ),

(Sigma Aldrich , St Louis , Mo.) and 20 ug /ml Nalidixic acid
( Acros Organics , NJ) . The plates were incubated anaerobi
cally at 37° C . for 14 days .
[0067 ] Screening for Isolates Against Streptococcus bovis
and Fusobacterium necrophorum
[0068 ] On day 14 , colonies were picked into 96 -well
plates containing tryptic soy broth (TSB ) (BD BactoTM ,
Sparks MD ) and were incubated anaerobically and aerobi
cally at 37° C . Screening for isolates that are inhibitory
towards Streptococcus bovis and Fusobacterium necropho

acid ), essential oils ( e . g ., eucalyptus , chenopodium , ylang

cultures of Streptococcus bovis ( ATCC 700410 ( JB1) ) and

parabens include , for example , methylparaben (E number

E218 ), ethylparaben (E214 ), propylparaben (E216 ), butyl
paraben and heptylparaben (E209 ). Less common parabens

fatty acids ( e. g., oleic acid , lauric acid , myristic acid , capric

ylang, L -menthol), terpenes (e .g., sesquiterpene ), terpe
noids, oxazolidinones (e. g., 4 -decyloxazolidin - 2 -one ), and
urea.

[ 0061] In some forms, Aneurinibacillus migulanus and/or

Aneurinibacillis aneurinilyticus or extracts thereof are
administered separately . In other forms, they are adminis
tered together. Preferably the combination of Aneuriniba

cillus migulanus and /or Aneurinibacillis aneurinilyticus or

extracts thereof will act synergistically.

[0062] When producing a lyophilized form of Aneurini

bacillus migulanus and / or Aneurinibacillis aneurinilyticus,

overnight cultures were centrifuged at 3000xg for 15 min at
room temperature and the resulting cell pellet was sus

pended in 10 ml of 20 % glycerol in spent media resuspen
sion solution (the media collected after centrifugation was
mixed with 50 % sterile glycerol to generate a 20 % resus
pension solution ). The resulting cell suspension was snap
frozen in liquid nitrogen and was then freeze dried to obtain
a freeze dried viable cell product. 10 milligramsof the freeze
dried cells were suspended in peptone water and was spread
on brain heart infusion agar plates to determine viable
colony forming units (CFUS) per milligram of freeze dried

product.
[0063] The following examples further illustrate specific
embodiments of the present disclosure ; however, the fol
lowing illustrative examples should notbe interpreted in any
way to limit the disclosure .

rum was performed as follows. Briefly , 100 ul of overnight

2 -day cultures of Fusobacterium necrophorum
BBLTM , Sparks,MD ) plates and were spotted with isolates .
The Streptococcus bovis test organism was grown on TSB
and Fusobacterium necrophorum was grown on cooked
meatmedium (Hardy Diagnostics ). The plating was done in
duplicate and was incubated both aerobically and anaerobi
cally at 37° C . Plates were checked periodically for clear
( ATCC27852 ), were plated on Brain Heart Infusion (BD

zones around the isolates , which was indicative of the isolate
producing an inhibitory product against the test strain .

Positive isolates were regrown from the 96 -well plates and
glycerol stocks were prepared for archiving, which con
tained 20 % glycerol. Two isolates with the capacity to
inhibit the growth of Streptococcus bovis and Fusobacte
rium necrophorum were identified for further investigation
( see FIG . 1) .

[0069] Characterization of the Microbial Strains

100701 To characterize the microbial isolates and to con
firm the identity of the test strains, 16S rRNA gene was

sequenced . Briefly , overnight cultures of each strain were
used for DNA extraction using the QUICKEXTRACTTM

Bacteria DNA extraction kit (Epicenter , Madison , Wis .)
according to the manufacturer 's protocol. The resulting
DNA was used for PCR using universal 16S rRNA primers
(27F and 1492R ) ( Baker et al., Review and re -analysis of
domain - specific 16S primers , J . Microbiol. Methods 2003 ,

55 ( 3): 541-555 ). The PCR was done using the TerraTM PCR
Direct polymerase mix according to the manufacturer 's

Sep . 5 , 2019

US 2019 /0269740 A1
protocol (Clonetech Laboratories, Mountain view , CA ). The

[0075] Growth curves of Streptococcus bovis in the pres
ence of the cell lysate of Aneurinibacillus anerinilyticus

PCR conditions were , 98° C . for 2 minutes , followed by 35
cycles of 98° C . for 10 seconds, 60° C . for 30 seconds, and

UNL P2C12

68° C . for 90 seconds . A final extension of 68° C . for 4

[0076 ] Growth curves for Streptococcus bovis were per

minutes was used at the end of the 35 cycles . The PCR
products were visualized using agarose gel electrophoresis
to ensure a single product . The resulting product was puri
fied using shrimp alkaline phosphatase and exonuclease as
described in Sambrook et al., Molecular Cloning: A Labo
ratory Manual, 2 edn . New York : Cold Spring Harbor
Laboratory Press ; 1989 , and was sequenced from both
directions using the 27F and 1492 primers . Sequencing was

formed using cell extracts of Aneurinibacillus anerinilyticus
UNLP2C12 . Briefly , an overnight culture of Streptococcus
bovis was diluted in sterile media to bring the OD595 to 0 . 2

units. One hundred microliters of the diluted culture was
dispensed into wells of a 96 -well sterile culture plate and the
following treatments were imposed each in triplicate .

Samples included : Blank ( only sterile media ), Cells (0 .2 OD
culture cells ), Cells + 30 ul of the lysate , Cells + 50 ul of the

performed at Eurifins Genomics according to their proto
cols. The sequencing results generated were matched against
the NCBI non - redundant database and the ribosomal data

bought up to 150 ul using sterile media except for the

(RDP - II): sequences and tools for high - throughput rRNA
analysis . Nucleic Acids Res 2005 , 33 :D294 -296 ; Maidak et

anaerobically using an anaerobic jar at 37° C . The cell

al., The RDP -II (Ribosomal Database Project ). Nucleic

at 0 , 4 , 22 .75 , and 27 hours of incubation . See Table 1 and
FIG . 5 . Growth curves for Fusobacterium necrophorum was
not performed as this organism is a strict anaerobe and
therefore hard to go in and out of the anaerobic jar to

base project (Cole et al., The Ribosomal Database Project
Acids Res 2001, 29 ( 1 ) : 173 - 174 ) to identify the taxonomic
classification of the unknown isolates and also to verify the

taxonomy of the test strains (SEQ ID NO : 1 and SEQ ID
NO : 2 ) .

[0071 ] Preparing Cell Extracts for Antimicrobial Assays

lysate, Cells + lysis buffer . Volumes of all the wells were

treatment with Cells + 50 ul of the lysate as the volume was

already 150 ul in this treatment. The plate was incubated
growth was measured using optical density (OD at 595 nm )

maintain growth .

TABLE 1

[0072 ] Based on the 16S sequencing results, both isolates

were identified to belong to the genus Aneurinibacillus ( A .
migulanus (SEQ ID NO :2 ) and A . anerinilyticus (SEQ ID

NO : 1 )). Based on published studies (Berditsch M , Afonin S ,

Time

cillus brevis ) to produce the antibiotic gramicidin S is

0 hours

Ulrich A S : The ability of Aneurinibacillus migulanus (Ba

correlated with phenotype variation . Appl Environ Microbiol
2007, 73 (20 ):6620 -6628 ), the cell extracts of the two iso
lates were purified . Briefly, 5 ml of the cultures were

4 hours

The supernatant was collected and lyophilized to evaluate

22. 75 hours

centrifuged at 3000xg for 15 minutes at room temperature .
secreted inhibitory product. Additionally, the cell pellet was
resuspended in the lysis buffer ( 150 mM NaCl and 20 mM

27 . 0 hours

HCI) and was incubated at 80° C . for 15 minutes, followed
by addition of absolute ethanol ( 1 : 1 mix - final concentra

Cells +

Cells +

0 .166

Blank

Cells + 30 ul 50 ul lysis /Extraction
Cells
Extract Extract
Buffer

0 .058

0 . 114

0 .059
0 .047
0 .049
0 .064
0 .047
0 .049
0 .066
0 .052
0 .047

0 .11
0 .104

0 . 139
0 . 149
0 . 196

0 .189
0 . 187
0 . 179

0 . 121

0 .262

0 . 152

0 . 129

0 .259

0 . 198

0 . 159
0 . 167
0 . 142
0 . 15
0 . 15
0 . 137

0 . 191

0 . 124
0 . 124
0 .76

0 . 241

0 .071

0 .833
0 .795
0 .777
0 .814
0 .828

0 .064

0 .917

0 . 15

0 . 168

0 . 202
0 . 191

0 . 192

0 . 185
0 . 186
0 . 195
0 . 184

0 .123

0 .844
0 . 836
0 .764
1 . 137

0 .957

tion of 50 % ). The slurry was then incubated at room

temperature with gentle horizontal agitation for 1 hour.

Following , extraction with ethanol, the slurry was centri
fuged and the supernatant was collected , which contained

the ethanoilic cell extract.

[0073 ] Antimicrobial Assays Against Streptococcus bovis
[0074 ] Both the ethanolic cell extract and the lyophilized
and Fusobacterium necrophorum

cell free media were used for agar disk diffusion antimicro
bial assays . The Kirby -Bauer Disk Diffusion Susceptibility

test was performed as described in Hudzcki: Kirby-Bauer

Disk Diffusion Susceptibility Test Protocol: American Soci

ety of microbiology ; 2009 , with the exception of using
from BD BBLTM , Sparks, MD ) instead of regular Mueller
Hinton agar plates without blood . This was done because of
the fastidious nature of Fusobacterium necrophorum . In

Mueller Hinton agar plates with 5 % sheep blood (purchased

[0077 ] In Vitro Analysis of pH Control During Acidosis
Induction

10078 ] The in vitro analysis was performed . Briefly, Aneu
rinibacillus anerinilyticus UNL P2C12 was grown overnight
and used to inoculate 1 L culture media to grow enough cells
for and to extract adequate amounts of cell lysate for the in

vitro experiments . The cultures were grown overnight aero

bically at 37°C . This was done because the Aneurinibacillus

anerinilyticus UNL P2C12 isolate is facultative and can be
grown both aerobically and anaerobically , but grows faster
aerobically . Part of the overnight growth was flash frozen in
liquid nitrogen in the presence of 20 % glycerol to use as live

culture inoculants in the in vitro experiments . The rest of the
culture was used to extract the cell lysate as described above .
Glucose was used to induce acidosis as described by Hutton
et al. (In Vitro Screening of Plant Resources for Extra

nutritional Attributes in Ruminants : Nuclear and Related

addition to the assays, a control assay was performed to

Methodologies Springer; 2009: 159 - 189). The following

demonstrate that the inhibition of the test strains were a

treatments were used .

result of the inhibitory compound and not a result of the

extraction/lysis buffer used . See FIGS. 2 - 4 for results of the
antimicrobial assays . The blood agar plate assays also dem
onstrated that the Aneurinibacillus migulanus strain is

hemolytic . All incubations were performed in an anaerobic
jar at 37° C .

Rumen Fluid (mL)
Uninduced

Induced

10
10

D - glucose (g)

Treatment
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was poured to a large beaker and was stirred . Ten milliliters
of the rumen fluid was added to each tube inside the

-continued
Rumen Fluid (mL)

D -glucose (g )

Treatment

10
10

Cell Extract

Cell Stock

500 ul

1000 ul
2000 ul

10

Cell Stock

[0079 ] Briefly , rumen samples were collected anaerobi
cally into a warm thermos as described by Hutton et al. The

rumen samples were collected from a fistulated steer 2 hours
after feeding . The rumen fluid collected was transported to
the laboratory and was opened inside the anaerobic chamber.

This process from sampling to opening in the chamber took
between 15 - 20 minutes. Inside the chamber, the rumen fluid

anaerobic chamber. All tubes except for the uninduced

treatment received 1 gram of glucose and was used to induce
tubes were sealed using butyl rubber stoppers and were
crimped with aluminum caps. The gas was equilibrated
before bringing the tubes out of the anaerobic chamber using
a 23 - gauge needle . The sealed tubes were brought out ofthe
anaerobic chamber and were vortexed to mix the contents
and glucose and were incubated at 39° C . with gentle
agitation (50 rpm ).
[0080 ] Tubes were removed at 0 , 1, 2 , 3 , 4 , 5 , 6 , 7, 8 hours .
Each tube was opened and the pH was recorded . Results of
the in vitro assay are shown in FIG . 6 .
acidosis . The treatments were imposed as shown above . The

SEQUENCE LISTING

< 160 > NUMBER OF SEQ ID NOS : 2
< 210 > SEQ ID NO 1
V

V

1 > LENGTH : 804
212 > TYPE : DNA

< 213 > ORGANISM : Aneurinibacillus aneurinolyticus

< 400 > SEQUENCE : 1

cttgctcttc ggcggttagc ggcggacggg tgagtaacac gtaggcaacc tgcctgtacg
actgggataa ctccgggaaa ccggagctaa taccggatac gtttttcaga ccgcatggto
tgaaagagaa agacctttgg tcacgtacag atgggcctgc ggcgcattag ctagttggtg

gggtaacggc
gggactgaga
acgaaagtct
gttgttaggg

ctaccaaggc
cacggcccag
gacggagcaa
aagaaccgcc

gacgatgcgt
actcctacgg
cgccgcgtga
gggatgacct

agccgacctg
gaggcagcag
acgatgaagg
cccggtctga

agagggtgat
tagggaatct
ttttcggatc
cggtacctaa

60
120

180

cggccacact
tccgcaatgg
gtaaagttct
cgagaaagcc

420

ccggctaact acgtgccagc agccgcggta atacgtaggg ggcaagcgtt gtccggaatt

480

attgggcgta aagcgcgcgc aggcggcttc ttaagtcagg tgtgaaagcc cacggctcaa
ccgtggaggg ccacttgaaa ctgggaggct tgagtgcagg agaggagagc ggaattccac
gtgtagcggt gaaatgcgta gagatgtgga ggaacacocg tggcgaaggc ggctctctgg

540

cctgtaactg acgctgaggc gcgaaagcgt ggggagcgaa caggattaga taccctggta
gtccacgccg taaacgttga gtgctaggtg ttggggactc caatcctcag tgccccagct
aacgcaataa gcactccgcc tggg

240

300
360

600
660

720

780
804

< 210 > SEQ ID NO 2

N

< 211 > LENGTH : 755
< 212 > TYPE : DNA

< 213 > ORGANISM : Aneurinibacillus migulanus
< 400 > SEQUENCE : 2
cagagcttgc tcttcggcgg ttagcggcgg acgggtgagt aacacgtagg caacctgcct

60

gtacgactgg gataactccg ggaaaccgga getaataccg gatacttctt tcagaccgca
tggtctgaaa gggaaagacc tttggtcacg tacagatggg cctgcggcgc attagctagt
tggtggggta acggcctacc aaggcgacga tgcgtagccg acctgagagg gtgatcggcc

120

acactgggac tgagacacgg cccagactcc tacgggaggc agcagtaggg aatcttccgc

300

180

240
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- continued
aatggacgaa agtctgacgg agcaacgccg cgtgaacgat gaaggttttc ggatcgtaaa

360

gttctgttgt tagggaagaa ccgccgggat gacctcccgg tctgacggta cctaacgaga

420

aagccccggc taactacgtg ccagcagccg cggtaatacg tagggggcaa gcgttgtccg

480

gaattattgg gcgtaaagcg cgcgcaggcg gottcttaag tcaggtgtga aagcccacgg

540

ctcaaccgtg gagggccact tgaaactggg aagcttgagt gcaggagagg agagoggaat
tccacgtgta gcggtgaaat gcgtagagat gtggaggaac acccgtggcg aaggcggctc
tctggcctgt aactgacgct gaggcgcgaa agcgtgggga gcgaacagga ttagataccc

600

tggtagtcca cgccgtaaac gttgagtgct aggtg

755

1 . A composition comprising:
a . from about 108 to about 1011 colony forming units
(CFU ) of a bacterial strain or extract thereof selected
from the group selected from the group consisting of
Aneurinibacillus migulanus, Aneurinibacillus aneu
rinilyticus, and any combination thereof; and
b . a prebiotic selected from the group consisting of
soluble starch , yeast extract, oligosaccharides, polysac
charides, and other prebiotics that contain fructose ,
xylose , soya , galactose , glucose , mannose , and any
combination thereof in an amount from about 1 . 0 g / L
to about 10 .0 g / L of the composition .

2 . (canceled )

3 . The composition of claim 1, wherein the composition
includes both Aneurinibacillus migulanus or an extract
thereof, Aneurinibacillus aneurinilyticus or an extract

thereof.

4 -5 . ( canceled )
6 . The composition of claim 1 ,wherein the bacterial strain
or extract thereof is in a lyophilized form .
7. The composition of claim 6 , wherein the lyophilized
form further comprises glycerol.
8 . The composition of claim 1 , wherein the extract of the

660
720

livestock feed selected from the group consisting of cattle
feed , pig feed , chicken feed , bison feed , buffalo feed , duck
feed and turkey feed .
13 - 14 . ( canceled )

15 . The method as set forth in claim 11 , wherein the
topical composition is in a form selected from the group
consisting of a spray composition , a lotion , an ointment, a
footbath , or any combination thereof.
16 - 17 . ( canceled )

18 . The method as set forth in claim 10 , wherein the
companion animal, and poultry .

subject is selected from the group consisting of livestock ,

19 . The method as set forth in claim 10 , further compris
ing the step of administering an effective amount of a

prebiotic.
20 . The method as set forth in claim 10 , wherein the

effective amount of the bacterial strain comprises from about

108 to about 1011 colony forming units (CFU ).
21 -43. (canceled )

44 . A method of reducing the incidence or severity of a

condition selected from the group consisting of acidosis ,

liver abscesses, foot rot, or any combination thereof in a

biological composition comprises at least one bacteroicin

subject in need thereof, the method comprising administer

selected from the group consisting of Carnocyclin A , Zoocin

selected from the group consisting ofAneurinibacillus migu

A , Enterolysin A , Linocin M18 , uviB , and any combination
9 . The composition of claim 1 , further comprising a
component selected from the group consisting of one or
thereof.

more excipients , carriers , active ingredients , dissolution

agents, surfactants, antioxidants, antiseptics, preservatives,
penetrants , and any combination thereof.
10 . A method of inhibiting a bacteria selected from the
group consisting of Streptococcus bovis, Fusobacterium
necrophorum , Acranobacterium (Actinomyces ) pyogenes
and any combination thereof in a subject in need thereof, the
method comprising administering to the subject an effective
amount of a bacterial strain selected from the group con
sisting of Aneurinibacillus migulanus or an extract thereof,
Aneurinibacillus aneurinilyticus or an extract thereof and
any combination thereof.

ing to the subject an effective amount of a bacterial strain

lanus or an extract thereof, Aneurinibacillus aneurinilyticus

or an extract thereof, and any combination thereof.

45 . The method as set forth in claim 44 , wherein the
bacterial strain or extract thereof is administered in a form

selected from the group consisting of a direct fed microbial
product, a feed additive , a topical composition , a toothpaste ,
or any combination thereof.
46 . The method as set forth in claim 45 , wherein the direct
fed microbial product can be used to supplement at least one
livestock feed selected from the group consisting of cattle

feed , pig feed , chicken feed , bison feed , buffalo feed , duck
feed and turkey feed .

47. ( canceled )
48. The method as set forth in claim 44 , wherein the

effective amount of the bacterial strain administered is from

11 . The method as set forth in claim 10 , wherein the
bacterial strain or extract thereof is administered in a form

about 10° to about 10 " cells per head per day.
49. The method as set forth in claim 44, wherein the

product, a feed additive , a toothpaste , a topical composition ,
or any combination thereof.
12 . The method as set forth in claim 11, wherein the direct
fed microbial product can be used to supplement at least one

companion animal, and poultry .
50 . The method as set forth in claim 44 , further compris
ing the step of administering an effective amount of a

selected from the group consisting of a direct fed microbial

subject is selected from the group consisting of livestock ,
prebiotic .
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51 . The method as set forth in claim 44 , wherein the
108 to about 1011 colony forming units (CFU ).
52-68. (canceled )

effective amount of the bacterial strain comprises from about
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